home / stock / agn:cc / agn:cc news

AGN:CC News and Press, Algernon Pharmaceuticals Inc.

Stock Information
Company Name: Algernon Pharmaceuticals Inc.
Stock Symbol: AGN:CC
Market: CNQC
Menu
AGN:CC AGN:CC Quote AGN:CC Short AGN:CC News AGN:CC Articles AGN:CC Message Board
Get AGN:CC Alerts

News, Short Squeeze, Breakout and More Instantly...
AGN:CC - Algernon Pharmaceuticals Reports Results of Study Showing 93% Cough Suppression with Ifenprodil

VANCOUVER, British Columbia, July 16, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company, is pleased to report that ifenprodil achieved...
AGN:CC - Algernon Pharmaceuticals Engages ICP Securities Inc. for Automated Market Making Services

VANCOUVER, British Columbia, May 21, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to announce that it ha...

AGN:CC - Algernon NeuroScience and the Centre for Human Drug Research to Present DMT Phase 1 Stroke Clinical Data at the Interdisciplinary Conference on Psychedelic Research June 6 - 8th, 2024

VANCOUVER, British Columbia, April 24, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to announce that its...

AGN:CC - Algernon Pharmaceuticals CEO Christopher J. Moreau to Be Featured on Radius Research's Pitch, Deep Dive and Q&A Webinar on April 16th, 2024

VANCOUVER, British Columbia, April 11, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), is pleased to invite investors and other interested parties to participate in an upcoming speci...
AGN:CC - Algernon Pharmaceuticals to Move Forward with Psychedelic Drug DMT Stroke Research Program as its Lead Asset

VANCOUVER, British Columbia, April 01, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to announce that it pl...

AGN:CC - Algernon Pharmaceuticals Strikes Deal to Advance Ifenprodil in Chronic Cough Treatment

--News Direct-- Algernon Pharmaceuticals CEO Christopher Moreau joined Steve Darling from Proactive to announce a significant agreement regarding the company's drug, Ifenprodil with U.S. Based Seyltx. Originally discovered in Japan and not utilized in the US or Europe, Ifenprodil was init...

AGN:CC - Canadian Investment Regulatory Organization Trade Resumption - AGN

Canadian Investment Regulatory Organization Trade Resumption - AGN Canada NewsWire VANCOUVER, BC , March 27, 2024 /CNW/ - Trading resumes in: Company: Algernon Pharmaceuticals Inc. CSE Symbol: AGN All Issues: Yes Resumption (ET): 12:45 PM CIRO...
AGN:CC - Algernon Pharmaceuticals Announces Closing of the Acquisition of its Chronic Cough Research Program by U.S. Based Seyltx for USD $2M and a 20% Equity Position

VANCOUVER, British Columbia, March 27, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to announce that it ha...

AGN:CC - Canadian Investment Regulatory Organization Trading Halt - AGN

Canadian Investment Regulatory Organization Trading Halt - AGN Canada NewsWire VANCOUVER, BC , March 27, 2024 /CNW/ - The following issues have been halted by CIRO: Company: Algernon Pharmaceuticals Inc. CSE Symbol: AGN All Issues: Yes Reason: Pending...

AGN:CC - Algernon Pharmaceuticals Receives Notice of Intention to Grant from Chinese Patent Office for Repirinast to Treat CKD

VANCOUVER, British Columbia, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a Canadian clinical stage pharmaceutical development company, is pleased to announce that it has ...
Next 10